Levenue 250 Tablet contains Levetiracetam 250 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Levenue 250 is commonly prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. The tablet is well-absorbed orally, exhibiting rapid bioavailability with minimal hepatic metabolism, which reduces the risk of drug interactions. Dosage should be individualized based on patient response and tolerability, with gradual titration recommended to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and behavioral symptoms such as irritability or mood changes. Caution is advised in patients with renal impairment, and dose adjustment may be necessary. Levenue 250 should be used under strict medical supervision, with regular monitoring for efficacy and potential adverse reactions. Abrupt discontinuation is discouraged to prevent seizure exacerbation. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients.